title: Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
abstract: In end-stage renal disease patients, various abnormalities of bone mineral metabolism adversely affect mortality. Hyperphosphatemia is known to adversely affect mortality and quality of life in chronic kidney disease patients and has been shown to be involved not only in the onset and progression of secondary hyperparathyroidism but also in vascular calcification. Thus, hyperphosphatemia is the main treatment target indicated in several guidelines for chronic kidney disease-mineral and bone disorder treatment. Phosphate binders are typically required for the management of hyperphosphatemia because dietary phosphorus restriction and phosphorus removal by hemodialysis alone are insufficient. We are able to prescribe five phosphate binders (calcium carbonate, sevelamer HCl, lanthanum carbonate (LaC), bixalomer, and ferric citrate) to Japanese hemodialysis patients. LaC is the most powerful noncalcium-containing phosphate binder for the treatment of hyperphosphatemia. In this chapter, we discuss the efficacy and safety of LaC, the safety of which has been under debate. In particular, we consider its toxic effects on the skeletal system. LaC is effective for hyperphosphatemia treatment in end-stage renal failure patients. It has been shown to be able to decrease serum fibroblast growth factor-23 levels. This result suggests that it may have beneficial effects on the cardiovascular system in patients undergoing renal replacement therapy. However, the effects of LaC remain obscure. Further investigations are required. No negative effects of LaC on bone metabolism or bone morphometry have been reported, but long-term clinical data are needed.
authors.affiliation: Division of Nephrology, Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Shigematsu
authors.forename: Masaki
authors.initials: M
authors.lastname: Ohya
authors.forename: Shigeo
authors.initials: S
authors.lastname: Negi
authors.forename: Asuka R
authors.initials: AR
authors.lastname: Masumoto
authors.forename: Yuri M
authors.initials: YM
authors.lastname: Nakashima
authors.forename: Yuka
authors.initials: Y
authors.lastname: Iwatani
authors.forename: Mari K
authors.initials: MK
authors.lastname: Moribata
authors.forename: Shintaro
authors.initials: S
authors.lastname: Yamanaka
authors.forename: Kouichi
authors.initials: K
authors.lastname: Tatsuta
authors.forename: Toru
authors.initials: T
authors.lastname: Mima
mesh_terms: D001842:Bone and Bones / Q000473:pathology; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood; D006801:Humans; D054559:Hyperphosphatemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D007811:Lanthanum / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D010710:Phosphates / Q000097:blood; D006435:Renal Dialysis; D013997:Time Factors
chemical_list: D010710:Phosphates; C119467:lanthanum carbonate; D005346:Fibroblast Growth Factors; D007811:Lanthanum; D000089703:Fibroblast Growth Factor-23